請用此 Handle URI 來引用此文件：
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/78981完整後設資料紀錄
| DC 欄位 | 值 | 語言 |
|---|---|---|
| dc.contributor.advisor | 何佳安 | |
| dc.contributor.author | Tung-Yaw Tsai | en |
| dc.contributor.author | 蔡東耀 | zh_TW |
| dc.date.accessioned | 2021-07-11T15:34:01Z | - |
| dc.date.available | 2023-08-23 | |
| dc.date.copyright | 2018-08-23 | |
| dc.date.issued | 2018 | |
| dc.date.submitted | 2018-08-15 | |
| dc.identifier.citation | 參考文獻
1. Wohlhueter, R.M., R.S. McIvor, and P.G. Plagemann, Facilitated transport of uracil and 5-fluorouracil, and permeation of orotic acid into cultured mammalian cells. J Cell Physiol, 1980. 104(3): p. 309-19. 2. Diasio, R.B. and B.E. Harris, Clinical pharmacology of 5-fluorouracil. Clin Pharmacokinet, 1989. 16(4): p. 215-37. 3. Sommer, H. and D.V. Santi, Purification and amino acid analysis of an active site peptide from thymidylate synthetase containing covalently bound 5-fluoro-2'-deoxyuridylate and methylenetetrahydrofolate. Biochem Biophys Res Commun, 1974. 57(3): p. 689-95. 4. Santi, D.V., C.S. McHenry, and H. Sommer, Mechanism of interaction of thymidylate synthetase with 5-fluorodeoxyuridylate. Biochemistry, 1974. 13(3): p. 471-81. 5. Houghton, J.A., D.M. Tillman, and F.G. Harwood, Ratio of 2'-deoxyadenosine-5'-triphosphate/thymidine-5'-triphosphate influences the commitment of human colon carcinoma cells to thymineless death. Clin Cancer Res, 1995. 1(7): p. 723-30. 6. Yoshioka, A., et al., Deoxyribonucleoside triphosphate imbalance. 5-Fluorodeoxyuridine-induced DNA double strand breaks in mouse FM3A cells and the mechanism of cell death. J Biol Chem, 1987. 262(17): p. 8235-41. 7. Aherne, G.W., et al., Immunoreactive dUMP and TTP pools as an index of thymidylate synthase inhibition; effect of tomudex (ZD1694) and a nonpolyglutamated quinazoline antifolate (CB30900) in L1210 mouse leukaemia cells. Biochem Pharmacol, 1996. 51(10): p. 1293-301. 8. Mitrovski, B., et al., Biochemical effects of folate-based inhibitors of thymidylate synthase in MGH-U1 cells. Cancer Chemother Pharmacol, 1994. 35(2): p. 109-14. 9. Webley, S.D., et al., Deoxyuridine triphosphatase (dUTPase) expression and sensitivity to the thymidylate synthase (TS) inhibitor ZD9331. Br J Cancer, 2000. 83(6): p. 792-9. 10. Ladner, R.D., The role of dUTPase and uracil-DNA repair in cancer chemotherapy. Curr Protein Pept Sci, 2001. 2(4): p. 361-70. 11. Grem, J.L. and P.H. Fischer, Enhancement of 5-fluorouracil's anticancer activity by dipyridamole. Pharmacol Ther, 1989. 40(3): p. 349-71. 12. Li, L.S., et al., DNA mismatch repair (MMR)-dependent 5-fluorouracil cytotoxicity and the potential for new therapeutic targets. Br J Pharmacol, 2009. 158(3): p. 679-92. 13. Wyatt, M.D. and D.M. Wilson, 3rd, Participation of DNA repair in the response to 5-fluorouracil. Cell Mol Life Sci, 2009. 66(5): p. 788-99. 14. Kufe, D.W. and P.P. Major, 5-Fluorouracil incorporation into human breast carcinoma RNA correlates with cytotoxicity. J Biol Chem, 1981. 256(19): p. 9802-5. 15. Glazer, R.I. and L.S. Lloyd, Association of cell lethality with incorporation of 5-fluorouracil and 5-fluorouridine into nuclear RNA in human colon carcinoma cells in culture. Mol Pharmacol, 1982. 21(2): p. 468-73. 16. Kanamaru, R., et al., The inhibitory effects of 5-fluorouracil on the metabolism of preribosomal and ribosomal RNA in L-1210 cells in vitro. Cancer Chemother Pharmacol, 1986. 17(1): p. 43-6. 17. Ghoshal, K. and S.T. Jacob, Specific inhibition of pre-ribosomal RNA processing in extracts from the lymphosarcoma cells treated with 5-fluorouracil. Cancer Res, 1994. 54(3): p. 632-6. 18. Santi, D.V. and L.W. Hardy, Catalytic mechanism and inhibition of tRNA (uracil-5-)methyltransferase: evidence for covalent catalysis. Biochemistry, 1987. 26(26): p. 8599-606. 19. Randerath, K., et al., Specific effects of 5-fluoropyrimidines and 5-azapyrimidines on modification of the 5 position of pyrimidines, in particular the synthesis of 5-methyluracil and 5-methylcytosine in nucleic acids. Recent Results Cancer Res, 1983. 84: p. 283-97. 20. Patton, J.R., Ribonucleoprotein particle assembly and modification of U2 small nuclear RNA containing 5-fluorouridine. Biochemistry, 1993. 32(34): p. 8939-44. 21. Doong, S.L. and B.J. Dolnick, 5-Fluorouracil substitution alters pre-mRNA splicing in vitro. J Biol Chem, 1988. 263(9): p. 4467-73. 22. Samuelsson, T., Interactions of transfer RNA pseudouridine synthases with RNAs substituted with fluorouracil. Nucleic Acids Res, 1991. 19(22): p. 6139-44. 23. Carrico, C.K. and R.I. Glazer, Effect of 5-fluorouracil on the synthesis and translation of polyadenylic acid-containing RNA from regenerating rat liver. Cancer Res, 1979. 39(9): p. 3694-701. 24. Matherly, L.H., et al., Role for cytosolic folate-binding proteins in the compartmentation of endogenous tetrahydrofolates and the 5-formyl tetrahydrofolate-mediated enhancement of 5-fluoro-2'-deoxyuridine antitumor activity in vitro. Cancer Res, 1990. 50(11): p. 3262-9. 25. Park, J.G., et al., Enhancement of fluorinated pyrimidine-induced cytotoxicity by leucovorin in human colorectal carcinoma cell lines. J Natl Cancer Inst, 1988. 80(19): p. 1560-4. 26. Nadal, J.C., et al., In vivo potentiation of 5-fluorouracil by leucovorin in murine colon carcinoma. Biomed Pharmacother, 1988. 42(6): p. 387-93. 27. Wright, J.E., et al., Selective expansion of 5,10-methylenetetrahydrofolate pools and modulation of 5-fluorouracil antitumor activity by leucovorin in vivo. Cancer Res, 1989. 49(10): p. 2592-6. 28. Dolnick, B.J. and Y.C. Cheng, Human thymidylate synthetase. II. Derivatives of pteroylmono- and -polyglutamates as substrates and inhibitors. J Biol Chem, 1978. 253(10): p. 3563-7. 29. Radparvar, S., P.J. Houghton, and J.A. Houghton, Effect of polyglutamylation of 5,10-methylenetetrahydrofolate on the binding of 5-fluoro-2'-deoxyuridylate to thymidylate synthase purified from a human colon adenocarcinoma xenograft. Biochem Pharmacol, 1989. 38(2): p. 335-42. 30. Adjei, A.A., A review of the pharmacology and clinical activity of new chemotherapy agents for the treatment of colorectal cancer. Br J Clin Pharmacol, 1999. 48(3): p. 265-77. 31. Porter, D.J., et al., Mechanism-based inactivation of dihydropyrimidine dehydrogenase by 5-ethynyluracil. J Biol Chem, 1992. 267(8): p. 5236-42. 32. Takechi, T., et al., Antitumor activity and low intestinal toxicity of S-1, a new formulation of oral tegafur, in experimental tumor models in rats. Cancer Chemother Pharmacol, 1997. 39(3): p. 205-11. 33. Spector, T., et al., Attenuation of the antitumor activity of 5-fluorouracil by (R)-5-fluoro-5,6-dihydrouracil. Cancer Res, 1995. 55(6): p. 1239-41. 34. Johnston, P.G. and S. Kaye, Capecitabine: a novel agent for the treatment of solid tumors. Anticancer Drugs, 2001. 12(8): p. 639-46. 35. Miwa, M., et al., Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. Eur J Cancer, 1998. 34(8): p. 1274-81. 36. Cao, D., et al., Uridine phosphorylase (-/-) murine embryonic stem cells clarify the key role of this enzyme in the regulation of the pyrimidine salvage pathway and in the activation of fluoropyrimidines. Cancer Res, 2002. 62(8): p. 2313-7. 37. Benz, C., et al., Optimal schedule of methotrexate and 5-fluorouracil in human breast cancer. Cancer Res, 1982. 42(5): p. 2081-6. 38. Bertino, J.R., E. Mini, and D.J. Fernandes, Sequential methotrexate and 5-fluorouracil: mechanisms of synergy. Semin Oncol, 1983. 10(2 Suppl 2): p. 2-5. 39. McSheehy, P.M., M.J. Prior, and J.R. Griffiths, Enhanced 5-fluorouracil cytotoxicity and elevated 5-fluoronucleotides in the rat Walker carcinosarcoma following methotrexate pre-treatment: a 19F-MRS study in vivo. Br J Cancer, 1992. 65(3): p. 369-75. 40. Sawyer, R.C., et al., Inhibition by methotrexate of the stable incorporation of 5-fluorouracil into murine bone marrow DNA. Biochem Pharmacol, 1989. 38(14): p. 2305-11. 41. Cadman, E., R. Heimer, and C. Benz, The influence of methotrexate pretreatment on 5-fluorouracil metabolism in L1210 cells. J Biol Chem, 1981. 256(4): p. 1695-704. 42. Leyland-Jones, B. and P.J. O'Dwyer, Biochemical modulation: application of laboratory models to the clinic. Cancer Treat Rep, 1986. 70(1): p. 219-29. 43. Meta-analysis of randomized trials testing the biochemical modulation of fluorouracil by methotrexate in metastatic colorectal cancer. Advanced Colorectal Cancer Meta-Analysis Project. J Clin Oncol, 1994. 12(5): p. 960-9. 44. Liby, K.T., M.M. Yore, and M.B. Sporn, Triterpenoids and rexinoids as multifunctional agents for the prevention and treatment of cancer. Nat Rev Cancer, 2007. 7(5): p. 357-69. 45. Ovesna, Z., et al., Pentacyclic triterpenoic acids: new chemoprotective compounds. Minireview. Neoplasma, 2004. 51(5): p. 327-33. 46. Jang, S.M., et al., Ursolic acid enhances the cellular immune system and pancreatic beta-cell function in streptozotocin-induced diabetic mice fed a high-fat diet. Int Immunopharmacol, 2009. 9(1): p. 113-9. 47. Beveridge, T.H., T.S. Li, and J.C. Drover, Phytosterol content in American ginseng seed oil. J Agric Food Chem, 2002. 50(4): p. 744-50. 48. Imam, S., et al., Two triterpenes lupanone and lupeol isolated and identified from Tamarindus indica linn. Pak J Pharm Sci, 2007. 20(2): p. 125-7. 49. Huang, S.P., et al., Chemopreventive Potential of Ethanolic Extracts of Luobuma Leaves (Apocynum venetum L.) in Androgen Insensitive Prostate Cancer. Nutrients, 2017. 9(9). 50. Fernandez, A., et al., Anti-inflammatory effect of Pimenta racemosa var. ozua and isolation of the triterpene lupeol. Farmaco, 2001. 56(4): p. 335-8. 51. Geetha, T. and P. Varalakshmi, Effect of lupeol and lupeol linoleate on lysosomal enzymes and collagen in adjuvant-induced arthritis in rats. Mol Cell Biochem, 1999. 201(1-2): p. 83-7. 52. Ali, H., P.J. Houghton, and A. Soumyanath, alpha-Amylase inhibitory activity of some Malaysian plants used to treat diabetes; with particular reference to Phyllanthus amarus. J Ethnopharmacol, 2006. 107(3): p. 449-55. 53. Sudharsan, P.T., et al., Cardioprotective effect of pentacyclic triterpene, lupeol and its ester on cyclophosphamide-induced oxidative stress. Hum Exp Toxicol, 2005. 24(6): p. 313-8. 54. Sudhahar, V., et al., Protective effect of lupeol and lupeol linoleate in hypercholesterolemia associated renal damage. Mol Cell Biochem, 2008. 317(1-2): p. 11-20. 55. Prasad, S., N. Kalra, and Y. Shukla, Hepatoprotective effects of lupeol and mango pulp extract of carcinogen induced alteration in Swiss albino mice. Mol Nutr Food Res, 2007. 51(3): p. 352-9. 56. Hernandez-Perez, M., et al., Antimicrobial activity of Visnea mocanera leaf extracts. J Ethnopharmacol, 1994. 41(1-2): p. 115-9. 57. Saleem, M., Lupeol, a novel anti-inflammatory and anti-cancer dietary triterpene. Cancer Lett, 2009. 285(2): p. 109-15. 58. Geetha, T., P. Varalakshmi, and R.M. Latha, Effect of triterpenes from Crataeva nurvala stem bark on lipid peroxidation in adjuvant induced arthritis in rats. Pharmacol Res, 1998. 37(3): p. 191-5. 59. Saleem, M., et al., Lupeol modulates NF-kappaB and PI3K/Akt pathways and inhibits skin cancer in CD-1 mice. Oncogene, 2004. 23(30): p. 5203-14. 60. Saleem, M., et al., A novel dietary triterpene Lupeol induces fas-mediated apoptotic death of androgen-sensitive prostate cancer cells and inhibits tumor growth in a xenograft model. Cancer Res, 2005. 65(23): p. 11203-13. 61. Saleem, M., et al., Lupeol inhibits growth of highly aggressive human metastatic melanoma cells in vitro and in vivo by inducing apoptosis. Clin Cancer Res, 2008. 14(7): p. 2119-27. 62. Bani, S., et al., Suppression of T lymphocyte activity by lupeol isolated from Crataeva religiosa. Phytother Res, 2006. 20(4): p. 279-87. 63. Preetha, S.P., et al., Lupeol ameliorates aflatoxin B1-induced peroxidative hepatic damage in rats. Comp Biochem Physiol C Toxicol Pharmacol, 2006. 143(3): p. 333-9. 64. Hata, K., et al., Differentiation-inducing activity of lupeol, a lupane-type triterpene from Chinese dandelion root (Hokouei-kon), on a mouse melanoma cell line. Biol Pharm Bull, 2000. 23(8): p. 962-7. 65. Hata, K., K. Hori, and S. Takahashi, Role of p38 MAPK in lupeol-induced B16 2F2 mouse melanoma cell differentiation. J Biochem, 2003. 134(3): p. 441-5. 66. Hata, K., et al., Remodeling of actin cytoskeleton in lupeol-induced B16 2F2 cell differentiation. J Biochem, 2005. 138(4): p. 467-72. 67. Prasad, S., et al., Regulation of signaling pathways involved in lupeol induced inhibition of proliferation and induction of apoptosis in human prostate cancer cells. Mol Carcinog, 2008. 47(12): p. 916-24. 68. Siddique, H.R., et al., Lupeol, a novel androgen receptor inhibitor: implications in prostate cancer therapy. Clin Cancer Res, 2011. 17(16): p. 5379-91. 69. Saleem, M., et al., Lupeol inhibits proliferation of human prostate cancer cells by targeting beta-catenin signaling. Carcinogenesis, 2009. 30(5): p. 808-17. 70. He, Y., et al., Growth inhibition and apoptosis induced by lupeol, a dietary triterpene, in human hepatocellular carcinoma cells. Biol Pharm Bull, 2011. 34(4): p. 517-22. 71. Zhang, L., et al., Lupeol, a dietary triterpene, inhibited growth, and induced apoptosis through down-regulation of DR3 in SMMC7721 cells. Cancer Invest, 2009. 27(2): p. 163-70. 72. Siveen, K.S., et al., Negative regulation of signal transducer and activator of transcription-3 signalling cascade by lupeol inhibits growth and induces apoptosis in hepatocellular carcinoma cells. Br J Cancer, 2014. 111(7): p. 1327-37. 73. Saleem, M., et al., Lupeol, a fruit and vegetable based triterpene, induces apoptotic death of human pancreatic adenocarcinoma cells via inhibition of Ras signaling pathway. Carcinogenesis, 2005. 26(11): p. 1956-64. 74. Liu, Y., et al., Lupeol inhibits proliferation and induces apoptosis of human pancreatic cancer PCNA-1 cells through AKT/ERK pathways. Naunyn Schmiedebergs Arch Pharmacol, 2015. 388(3): p. 295-304. 75. Wu, X.T., et al., The enhanced effect of lupeol on the destruction of gastric cancer cells by NK cells. Int Immunopharmacol, 2013. 16(2): p. 332-40. 76. Tarapore, R.S., et al., The dietary terpene lupeol targets colorectal cancer cells with constitutively active Wnt/beta-catenin signaling. Mol Nutr Food Res, 2013. 57(11): p. 1950-8. 77. Krokan, H.E., R. Standal, and G. Slupphaug, DNA glycosylases in the base excision repair of DNA. Biochem J, 1997. 325 ( Pt 1): p. 1-16. 78. Lindahl, T., An N-glycosidase from Escherichia coli that releases free uracil from DNA containing deaminated cytosine residues. Proc Natl Acad Sci U S A, 1974. 71(9): p. 3649-53. 79. Otterlei, M., et al., Post-replicative base excision repair in replication foci. EMBO J, 1999. 18(13): p. 3834-44. 80. Nilsen, H., et al., Uracil-DNA glycosylase (UNG)-deficient mice reveal a primary role of the enzyme during DNA replication. Mol Cell, 2000. 5(6): p. 1059-65. 81. Akbari, M., et al., Repair of U/G and U/A in DNA by UNG2-associated repair complexes takes place predominantly by short-patch repair both in proliferating and growth-arrested cells. Nucleic Acids Res, 2004. 32(18): p. 5486-98. 82. Kavli, B., et al., hUNG2 is the major repair enzyme for removal of uracil from U:A matches, U:G mismatches, and U in single-stranded DNA, with hSMUG1 as a broad specificity backup. J Biol Chem, 2002. 277(42): p. 39926-36. 83. Pearl, L.H., Structure and function in the uracil-DNA glycosylase superfamily. Mutat Res, 2000. 460(3-4): p. 165-81. 84. Hendrich, B., et al., The thymine glycosylase MBD4 can bind to the product of deamination at methylated CpG sites (vol 401, pg 301, 1999). Nature, 2000. 404(6777): p. 525-525. 85. Luo, Y., M. Walla, and M.D. Wyatt, Uracil incorporation into genomic DNA does not predict toxicity caused by chemotherapeutic inhibition of thymidylate synthase. DNA Repair (Amst), 2008. 7(2): p. 162-9. 86. Doetsch, P.W. and R.P. Cunningham, The enzymology of apurinic/apyrimidinic endonucleases. Mutat Res, 1990. 236(2-3): p. 173-201. 87. Matsumoto, Y. and K. Kim, Excision of deoxyribose phosphate residues by DNA polymerase beta during DNA repair. Science, 1995. 269(5224): p. 699-702. 88. Prasad, R., et al., Human DNA polymerase beta deoxyribose phosphate lyase. Substrate specificity and catalytic mechanism. J Biol Chem, 1998. 273(24): p. 15263-70. 89. Caldecott, K.W., XRCC1 and DNA strand break repair. DNA Repair (Amst), 2003. 2(9): p. 955-69. 90. Grogan, B.C., et al., Effect of the thymidylate synthase inhibitors on dUTP and TTP pool levels and the activities of DNA repair glycosylases on uracil and 5-fluorouracil in DNA. Biochemistry, 2011. 50(5): p. 618-27. 91. Gadsden, M.H., et al., Dutp Pyrophosphatase Is an Essential Enzyme in Saccharomyces-Cerevisiae. Embo Journal, 1993. 12(11): p. 4425-4431. 92. Meyers, M., et al., A role for DNA mismatch repair in sensing and responding to fluoropyrimidine damage. Oncogene, 2003. 22(47): p. 7376-7388. 93. Fischer, J.A., S. Muller-Weeks, and S.J. Caradonna, Fluorodeoxyuridine modulates cellular expression of the DNA base excision repair enzyme uracil-DNA glycosylase. Cancer Res, 2006. 66(17): p. 8829-37. 94. Bulgar, A.D., et al., Removal of uracil by uracil DNA glycosylase limits pemetrexed cytotoxicity: overriding the limit with methoxyamine to inhibit base excision repair. Cell Death Dis, 2012. 3: p. e252. 95. Yan, Y., et al., Inhibition of uracil DNA glycosylase sensitizes cancer cells to 5-fluorodeoxyuridine through replication fork collapse-induced DNA damage. Oncotarget, 2016. 7(37): p. 59299-59313. 96. Huehls, A.M., et al., Genomically Incorporated 5-Fluorouracil that Escapes UNG-Initiated Base Excision Repair Blocks DNA Replication and Activates Homologous Recombination. Mol Pharmacol, 2016. 89(1): p. 53-62. 97. Welsh, S.J., S. Hobbs, and G.W. Aherne, Expression of uracil DNA glycosylase (UDG) does not affect cellular sensitivity to thymidylate synthase (TS) inhibition. Eur J Cancer, 2003. 39(3): p. 378-87. 98. Andersen, S., et al., Incorporation of dUMP into DNA is a major source of spontaneous DNA damage, while excision of uracil is not required for cytotoxicity of fluoropyrimidines in mouse embryonic fibroblasts. Carcinogenesis, 2005. 26(3): p. 547-55. 99. Pettersen, H.S., et al., UNG-initiated base excision repair is the major repair route for 5-fluorouracil in DNA, but 5-fluorouracil cytotoxicity depends mainly on RNA incorporation. Nucleic Acids Res, 2011. 39(19): p. 8430-44. 100. Kemmerich, K., et al., Germline ablation of SMUG1 DNA glycosylase causes loss of 5-hydroxymethyluracil- and UNG-backup uracil-excision activities and increases cancer predisposition of Ung-/-Msh2-/- mice. Nucleic Acids Res, 2012. 40(13): p. 6016-25. 101. Nagaria, P., et al., SMUG1 but not UNG DNA glycosylase contributes to the cellular response to recovery from 5-fluorouracil induced replication stress. Mutat Res, 2013. 743-744: p. 26-32. 102. An, Q., et al., 5-Fluorouracil incorporated into DNA is excised by the Smug1 DNA glycosylase to reduce drug cytotoxicity. Cancer Res, 2007. 67(3): p. 940-5. 103. Kunz, C., et al., Base excision by thymine DNA glycosylase mediates DNA-directed cytotoxicity of 5-fluorouracil. PLoS Biol, 2009. 7(4): p. e91. 104. Cortellino, S., et al., The base excision repair enzyme MED1 mediates DNA damage response to antitumor drugs and is associated with mismatch repair system integrity. Proc Natl Acad Sci U S A, 2003. 100(25): p. 15071-6. 105. Hagen, L., et al., Cell cycle-specific UNG2 phosphorylations regulate protein turnover, activity and association with RPA. EMBO J, 2008. 27(1): p. 51-61. 106. Welcker, M. and B.E. Clurman, Fbw7/hCDC4 dimerization regulates its substrate interactions. Cell Div, 2007. 2: p. 7. 107. Baehr, C.A., et al., Glycogen Synthase Kinase 3 (GSK-3)-mediated Phosphorylation of Uracil N-Glycosylase 2 (UNG2) Facilitates the Repair of Floxuridine-induced DNA Lesions and Promotes Cell Survival. J Biol Chem, 2016. 291(52): p. 26875-26885. 108. Al-Zain, A., et al., Cdc6 degradation requires phosphodegron created by GSK-3 and Cdk1 for SCFCdc4 recognition in Saccharomyces cerevisiae. Mol Biol Cell, 2015. 26(14): p. 2609-19. 109. Oh, M., et al., GSK-3 phosphorylates delta-catenin and negatively regulates its stability via ubiquitination/proteosome-mediated proteolysis. J Biol Chem, 2009. 284(42): p. 28579-89. 110. Ding, Q., et al., Degradation of Mcl-1 by beta-TrCP mediates glycogen synthase kinase 3-induced tumor suppression and chemosensitization. Mol Cell Biol, 2007. 27(11): p. 4006-17. 111. Dong, Q., et al., Glycogen synthase kinase-3-mediated phosphorylation of serine 73 targets sterol response element binding protein-1c (SREBP-1c) for proteasomal degradation. Biosci Rep, 2015. 36(1): p. e00284. 112. Welcker, M., et al., Nucleolar targeting of the fbw7 ubiquitin ligase by a pseudosubstrate and glycogen synthase kinase 3. Mol Cell Biol, 2011. 31(6): p. 1214-24. 113. Schmidt, C., et al., Acetyl-lupeolic acid inhibits Akt signaling and induces apoptosis in chemoresistant prostate cancer cells in vitro and in vivo. Oncotarget, 2017. 8(33): p. 55147-55161. 114. Helleday, T., et al., DNA repair pathways as targets for cancer therapy. Nat Rev Cancer, 2008. 8(3): p. 193-204. 115. Yan, Y., et al., Loss of Uracil DNA Glycosylase Selectively Resensitizes p53-Mutant and -Deficient Cells to 5-FdU. Mol Cancer Res, 2018. 16(2): p. 212-221. 116. Weeks, L.D., et al., Uracil DNA glycosylase (UNG) loss enhances DNA double strand break formation in human cancer cells exposed to pemetrexed. Cell Death Dis, 2014. 5: p. e1045. 117. Liu, Y., et al., Lupeol enhances inhibitory effect of 5-fluorouracil on human gastric carcinoma cells. Naunyn Schmiedebergs Arch Pharmacol, 2016. 389(5): p. 477-84. 118. Kuo, L.J. and L.X. Yang, Gamma-H2AX - a novel biomarker for DNA double-strand breaks. In Vivo, 2008. 22(3): p. 305-9. 119. Ayusawa, D., et al., Accumulation of DNA strand breaks during thymineless death in thymidylate synthase-negative mutants of mouse FM3A cells. J Biol Chem, 1983. 258(20): p. 12448-54. 120. Hori, T., et al., Chromosome breakage induced by thymidylate stress in thymidylate synthase-negative mutants of mouse FM3A cells. Cancer Res, 1984. 44(2): p. 703-9. 121. Kuong, K.J. and A. Kuzminov, Disintegration of nascent replication bubbles during thymine starvation triggers RecA- and RecBCD-dependent replication origin destruction. J Biol Chem, 2012. 287(28): p. 23958-70. 122. Waldman, B.C., et al., Induction of intrachromosomal homologous recombination in human cells by raltitrexed, an inhibitor of thymidylate synthase. DNA Repair (Amst), 2008. 7(10): p. 1624-35. 123. Dusseau, C., et al., Analysis of uracil DNA glycosylase in human colorectal cancer. Int J Oncol, 2001. 18(2): p. 393-9. | |
| dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/78981 | - |
| dc.description.abstract | 大腸直腸癌的發生率高居全球的第三位，而其中氟尿嘧啶 (5-FU)是最廣泛被用來當作一線化療的用藥。然而該藥物常因癌細胞所產生的抗性及其高劑量毒性限制了它的藥物療效。因此找到一個能提升5-FU藥物作用的組合藥物是必需的。天然物中蘊藏著許多有潛力被發展成新穎藥物的分子，羽扇豆醇(lupeol)就是一個具有多元藥物活性的天然化合物，其中也包括了抗癌活性。即使過往已有多篇報導著墨於羽扇豆醇的抗癌研究，但科學家關注的是羽扇豆醇藉由抑制NFκB、 PI3K/Akt、 Wnt/β-catenin…等等的路徑來毒殺癌細胞，本論文研究則著重於其抑制UNG (uracil DNA glycosylase)的能力。我們的結果顯示，羽扇豆醇抑制UNG的現象是在後轉譯的層級而非在mRNA的層級，且其所造成的UNG不穩定性可能是藉由proteasome對其的降解所達成的。再者，此羽扇豆醇抑制UNG的現象也確實造成了細胞中UDG活性的下降。由於5-FU會讓癌細胞併入更多的尿嘧啶和氟尿嘧啶到細胞核內DNA中，進而造成DNA損傷。因此UNG移除這些錯誤鹼基的UDG能力就顯得格外重要。所以基於此羽扇豆醇抑制UDG的現象，我們決定以羽扇豆醇和5-FU共處理DLD-1這株大腸癌細胞株，看是否能因此提升5-FU的藥物作用。根據我們MTT試驗的結果以及CDI (Coefficient of Drug Interaction)值的計算可知，此兩藥物的組合治療確實會有增效結果產生(CDI < 1)。除此之外，羽扇豆醇與5-FU的組合也增加了更多的γ-H2AX，且在彗星試驗中觀察到更多具有彗星狀DNA損傷之細胞。這說明了此二藥物的協同作用可能是因為增加細胞中的DNA損傷所造成的。綜合以上發現，羽扇豆醇對UNG的抑制作用具有提升大腸癌細胞對5-FU化學治療藥物敏感性的潛力。 | zh_TW |
| dc.description.abstract | Colorectal cancer (CRC) is the third most common cancer in the world and fluorouracil (5-FU) has been wildly used as the first line therapy for it. However, the treatment effect is often hampered by the development of drug resistance or toxicity at high doses. Therefore a new candidate serving as a co-drug that can sensitize colorectal cancer cells to 5-FU is in need. Natural compounds represent a significant source for the development of novel cancer therapies. Lupeol is one of these natural compounds that exhibits versatile pharmacological activities including anti-cancer capability. Though it has been reported previously that the cytotoxic effects lupeol exerted on cancer cells may be through the inhibition of signaling pathways such as NFκB, PI3K/Akt, Wnt/β-catenin, we herein focused on its ability in downregulating UNG (uracil DNA glycosylase), an initiator of BER (base excision repair). Our results showed that lupeol suppressed UNG in protein level rather than in transcriptional level, and the stability of UNG was likely affected via proteasome degradation. Furthermore, the UDG activity was found to be decreased after lupeol treatment. In consideration of the phenomenon we have observed, we decided to co-treat DLD-1 colorectal cancer cell line with lupeol and 5-FU (5-fluorouracil). 5-FU is known to prime cells to incorporate more uracil or fluorouracil into the genome, triggering the DNA damage. Therefore, once accumulation of a large number of uracil or FU occurred, the importance of UNG level became prominent. Our data showed that co-treatment of lupeol and 5-FU on DLD-1 colorectal cancer cells resulted in a CDI < 1 (Coefficient of Drug Interaction), indicating a synergism. In addition, combination of lupeol and 5-FU increased γ-H2AX and comet tail was observed by single cell gel electrophoresis, indicating that the synergistic effect may be due to the increment of DNA damages in cells. These findings suggest that the UNG inhibition effect by lupeol has the potential in sensitization colorectal cancer to 5-FU. | en |
| dc.description.provenance | Made available in DSpace on 2021-07-11T15:34:01Z (GMT). No. of bitstreams: 1 ntu-107-R03441012-1.pdf: 3942795 bytes, checksum: 0ad2191ad1631242436164948bb932ab (MD5) Previous issue date: 2018 | en |
| dc.description.tableofcontents | 目錄
1. 緒論 1 1.1. 大腸癌 1 1.1.1. 大腸癌概述 1 1.1.2. 大腸癌的分期與治療 2 1.2. 化療藥物5-氟尿嘧啶 (5-fluorouracil) 4 1.2.1. 5-FU之分子機轉 4 1.2.2. 5-FU的藥物合併治療 7 1.3. 羽扇豆醇 (lupeol) 10 1.3.1. 概述 10 1.3.2. 羽扇豆醇與癌症 11 1.4. 尿嘧啶糖苷酶超家族(UDG superfamily) 和鹼基去除修復(BER) 12 1.5. 化療藥物5-FU與UNG的關係 14 1.6. 研究動機 16 2. 材料與方法 18 2.1. 實驗藥品與儀器 18 2.1.1. 實驗藥品 18 2.1.2. 抗體 20 2.1.3. 引子 20 2.1.4. 儀器 21 2.2. 細胞培養 23 2.2.1. 細胞繼代 23 2.2.2. 細胞計數 23 2.2.3. 細胞冷凍與解凍 24 2.3. 蛋白質萃取與定量 25 2.3.1. 蛋白質萃取 25 2.3.2. 蛋白質定量 25 2.4. 西方墨點法 26 2.4.1. 試劑配置 26 2.4.2. 膠體製備 27 2.4.3. 樣品製備 27 2.4.4. SDS-PAGE 28 2.4.5. 轉印 (transfer) 28 2.4.6. 免疫墨點法 (immnoblot) 28 2.5. RNA萃取 29 2.6. qRT-PCR 30 2.7. UDG活性測試 32 2.8. 細胞存活率測試 34 2.8.1. MTT assay 34 2.8.2. Colony formation assay 34 2.9. 彗星試驗 35 3. 實驗結果與討論 37 3.1. 羽扇豆醇抑制DLD-1大腸癌細胞株UNG的表現量是在蛋白質層級而非在mRNA層級 37 3.2. 羽扇豆醇降低UNG細胞中穩定性是透過proteasome對其之降解 39 3.3. UDG活性試驗之實驗設計 41 3.4. UDG活性試驗之參數調整 44 3.5. 羽扇豆醇抑制DLD-1大腸癌細胞株UNG的酵素活性 47 3.6. 羽扇豆醇和5-FU對DLD-1大腸癌細胞株之作用: 增值 (proliferation) 和致腫瘤性 (tumorigenicity) 49 3.7. 羽扇豆醇和5-FU對 DLD-1大腸癌細胞株的藥物協同效應 53 3.8. 羽扇豆醇加強5-FU所造成的DNA損傷 56 4. 結論與未來展望 59 參考文獻 63 | |
| dc.language.iso | zh-TW | |
| dc.subject | DNA 損傷 | zh_TW |
| dc.subject | 藥物協同效應 | zh_TW |
| dc.subject | 尿嘧啶糖?? | zh_TW |
| dc.subject | 氟尿嘧啶 | zh_TW |
| dc.subject | 羽扇豆醇 | zh_TW |
| dc.subject | uracil DNA glycosylase | en |
| dc.subject | synergistic effect | en |
| dc.subject | DNA damage | en |
| dc.subject | lupeol | en |
| dc.subject | 5-fluorouracil | en |
| dc.title | 羽扇豆醇增強DLD-1大腸癌細胞株對化療藥物5-氟尿嘧啶敏感性的機制探討 | zh_TW |
| dc.title | The potential of lupeol in sensitization of DLD-1 colorectal cancer cell line to 5-FU via uracil DNA glycosylase inhibition | en |
| dc.type | Thesis | |
| dc.date.schoolyear | 106-2 | |
| dc.description.degree | 碩士 | |
| dc.contributor.oralexamcommittee | 徐士蘭,蕭寧馨,蘇純立,謝淑貞,吳立真 | |
| dc.subject.keyword | 羽扇豆醇,氟尿嘧啶,尿嘧啶糖??,DNA 損傷,藥物協同效應, | zh_TW |
| dc.subject.keyword | lupeol,5-fluorouracil,uracil DNA glycosylase,DNA damage,synergistic effect, | en |
| dc.relation.page | 76 | |
| dc.identifier.doi | 10.6342/NTU201803700 | |
| dc.rights.note | 有償授權 | |
| dc.date.accepted | 2018-08-16 | |
| dc.contributor.author-college | 生命科學院 | zh_TW |
| dc.contributor.author-dept | 生化科技學系 | zh_TW |
| dc.date.embargo-lift | 2023-08-23 | - |
| 顯示於系所單位： | 生化科技學系 | |
文件中的檔案：
| 檔案 | 大小 | 格式 | |
|---|---|---|---|
| ntu-107-R03441012-1.pdf 未授權公開取用 | 3.85 MB | Adobe PDF |
系統中的文件，除了特別指名其著作權條款之外，均受到著作權保護，並且保留所有的權利。